| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine
|
Hobart, Jeremy
|
|
2018
|
33 |
1 |
p. 61-79
|
article
|
| 2 |
Correction to: Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis
|
Papadopoulos, Dimitrios
|
|
2018
|
33 |
1 |
p. 93-97
|
article
|
| 3 |
Effects of Clozapine on the Gut: Cross-Sectional Study of Delayed Gastric Emptying and Small and Large Intestinal Dysmotility
|
Every-Palmer, Susanna
|
|
2018
|
33 |
1 |
p. 81-91
|
article
|
| 4 |
Impact of Antidepressant Use on the Trajectory of Alzheimer’s Disease: Evidence, Mechanisms, and Therapeutic Implications
|
Khoury, Rita
|
|
2018
|
33 |
1 |
p. 17-29
|
article
|
| 5 |
Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US
|
Sands, Tristan T.
|
|
2018
|
33 |
1 |
p. 47-60
|
article
|
| 6 |
Opioidergic Agents as Antidepressants: Rationale and Promise
|
Saxena, Parnika P.
|
|
2018
|
33 |
1 |
p. 9-16
|
article
|
| 7 |
Progress in Developing Pharmacologic Agents to Treat Bulimia Nervosa
|
McElroy, Susan L.
|
|
2018
|
33 |
1 |
p. 31-46
|
article
|
| 8 |
Revisiting the Concept of Subjective Tolerability to Antipsychotic Medications in Schizophrenia and its Clinical and Research Implications: 30 Years Later
|
Awad, A. George
|
|
2018
|
33 |
1 |
p. 1-8
|
article
|
Journal description